Therapeutic opportunities for targeting cellular senescence in progressive multiple sclerosis

Recent studies have implicated cellular senescence as a disease-related process linked to progressive forms of multiple sclerosis (MS). Herein, we present an overview of the current pharmacopeia of cellular senescence affecting compounds and evidence for their effects, if known, in murine and cellul...

Full description

Saved in:
Bibliographic Details
Published inCurrent opinion in pharmacology Vol. 63; p. 102184
Main Authors Sutter, Pearl A., McKenna, Mark G., Imitola, Jaime, Pijewski, Robert S., Crocker, Stephen J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.04.2022
Subjects
Animals
Cellular Senescence
Humans
Mice
Multiple Sclerosis - drug therapy
Multiple Sclerosis, Chronic Progressive - drug therapy
Online AccessGet full text

Cover

More Information
Summary:Recent studies have implicated cellular senescence as a disease-related process linked to progressive forms of multiple sclerosis (MS). Herein, we present an overview of the current pharmacopeia of cellular senescence affecting compounds and evidence for their effects, if known, in murine and cellular models of MS. Consideration is also given to the utility of these compounds for the treatment of progressive MS, with an examination of past and current clinical trials that have tested these agents, often for other purposes, in the MS patient population. Lastly, we discuss the implications and potential utility for targeting cellular senescence as a strategy to fulfil the unmet need of treatment options for the progressive MS population.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2022.102184